Refinement of the Alpha Aminooleic Acid Bioprosthetic Valve Anticalcification Technique

Gott, John Parker; Girardot, Marie-Nadia; Girardot, Jean-Marie D; Hall, James D.; Whitlark, Joseph D.; Horsley, William; Dorsey, Lynne M.A.; Levy, Robert J.; Chen, Weiliam; Schoen, Frederick J.; Guyton, Robert A.

doi:10.1016/s0003-4975(97)00118-5

Cited by 31 publications

(17 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several anti-calcification strategies such as treatments with surfactants, chelation reagents, and alcohols have shown prevention of calcification of BHVs in animal models and few of them are now used commercially in clinical settings [26–28]. Due to short time span of valve implants with anti-calcification treatments in humans (5–7 years), it is still awaited if such treatments make valves more durable.…”

Section: Discussionmentioning

confidence: 99%

A novel crosslinking method for improved tear resistance and biocompatibility of tissue based biomaterials

et al. 2015

View full text Add to dashboard Cite

Over 300,000 heart valve replacements are performed annually to replace stenotic and regurgitant heart valves. Bioprosthetic heart valves (BHVs), derived from glutaraldehyde crosslinked (GLUT) porcine aortic valve leaflets or bovine pericardium are often used. However, valve failure can occur within 12–15 years due to calcification and/or progressive degeneration. In this study, we have developed a novel fabrication method that utilizes carbodiimide, neomycin trisulfate, and pentagalloyl glucose crosslinking chemistry (TRI) to better stabilize the extracellular matrix of porcine aortic valve leaflets. We demonstrate that TRI treated leaflets show similar biomechanics to GLUT crosslinked leaflets. TRI treated leaflets had better resistance to enzymatic degradation in vitro and demonstrated better tearing toughness after challenged with enzymatic degradation. When implanted subcutaneously in rats for up to 90 days, GLUT control leaflets calcified heavily while TRI treated leaflets resisted calcification, retained more ECM components, and showed better biocompatibility.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel crosslinking method for improved tear resistance and biocompatibility of tissue based biomaterials

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The aortic root, valve, and proximal ascending aorta are fixed, cleaned, sized, mounted on a stent if needed, and packaged (and cryopreserved in the case of homografts). Today, most tissue valves are also treated with antimineralisation agents, to reduce tissue calcification [2,5]. BHF failure may occur due to general causes, that is, factors common to all valves or to factors specific to each particular device.…”

Section: Handling Of Biological Tissuementioning

confidence: 99%

Bioprosthetic Heart Valves: Impact of Implantation on Biomaterials

2013

View full text Add to dashboard Cite

Prosthetic heart valves are commonly used in the treatment of valvular heart disease. Mechanical valves are more durable than the bioprosthetic valves; however, the need for long-term anticoagulant therapy renders them unsuitable for some patient groups. In this paper we discuss the different types and models of bioprosthesis, and in particular, pericardial bioprosthesis. We also discuss the preimplantation preparation processes, as well as their postimplantation changes and modes of failure.

show abstract

“…The mechanism of suppression of calcification by the Tween‐80, a surfactant, is unclear 24 . Important in this respect is the observation that some anti‐mineralization agents (including AOA and ethanol) prevent experimental cusp calcification, but not calcification in the aortic wall 25 …”

Section: General Modes Of Failurementioning

confidence: 99%

Bioprosthetic heart valves: modes of failure

2009

View full text Add to dashboard Cite

Valve replacement started in 1960, with the surgeon now having a significant variety of prosthetic heart valves from which to choose. These valves are broadly divided into mechanical heart valves (MHV) and bioprosthetic heart valves (BHV). Improvements in the performance and ease of usage of BHV without the need for anticoagulant therapy are among the desired features of BHV and hence the increasingly preferred choice over their mechanical counterparts. However, with increased use the post-implantation complications have become more apparent, and these include: calcification, cusp tears, pannus growth, infective endocarditis, valve thrombosis and other factors specific to valve type. In this review we describe these complications in order to bring awareness among surgeons, clinicians and pathologists. Diagnosis, treatment and preventive measures, if taken in a timely manner, can help reduce their impact and further enhance the quality of life of patients with prosthetic heart valves.

show abstract

Refinement of the Alpha Aminooleic Acid Bioprosthetic Valve Anticalcification Technique

Cited by 31 publications

References 7 publications

A novel crosslinking method for improved tear resistance and biocompatibility of tissue based biomaterials

A novel crosslinking method for improved tear resistance and biocompatibility of tissue based biomaterials

Bioprosthetic Heart Valves: Impact of Implantation on Biomaterials

Bioprosthetic heart valves: modes of failure

Contact Info

Product

Resources

About